Compare Stocks → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYCNNASDAQ:EVFMOTCMKTS:PFSCFNASDAQ:PRQRNASDAQ:PRVB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCNCyclerion Therapeutics$3.14+13.4%$3.10$1.75▼$6.75$7.51M1.844,052 shs441 shsEVFMEvofem Biosciences$0.01$0.02$0.01▼$3.75$830K-1.12649,489 shs178,028 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/APRQRProQR Therapeutics$1.96-2.5%$2.14$1.11▼$3.29$163.52M0.21150,812 shs202,007 shsPRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCNCyclerion Therapeutics+10.95%-2.43%+1.29%+7.17%-44.83%EVFMEvofem Biosciences-4.70%+0.71%-21.98%-59.31%-99.44%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%PRQRProQR Therapeutics-2.49%+5.38%-18.33%-5.77%-11.31%PRVBProvention Bio0.00%0.00%0.00%0.00%0.00%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/APRQRProQR Therapeutics1.9091 of 5 stars3.55.00.00.01.90.00.0PRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCNCyclerion TherapeuticsN/AN/AN/AN/AEVFMEvofem Biosciences2.00HoldN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/APRQRProQR Therapeutics3.00Buy$3.6083.67% UpsidePRVBProvention BioN/AN/AN/AN/ACurrent Analyst RatingsLatest CYCN, PRVB, EVFM, PFSCF, and PRQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024PRQRProQR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.80 ➝ $2.003/14/2024PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $2.503/14/2024PRQRProQR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCNCyclerion Therapeutics$1.62M5.25N/AN/A$4.62 per share0.68EVFMEvofem Biosciences$18.22M0.04$1.42 per share0.01($2.64) per share-0.01PFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08PRQRProQR Therapeutics$7.05M22.62N/AN/A$0.55 per share3.56PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCNCyclerion Therapeutics-$5.26M-$5.51N/A∞N/AN/A-111.79%-74.10%5/9/2024 (Estimated)EVFMEvofem Biosciences$52.98M-$7.62N/A∞N/A290.81%-90.20%331.20%4/26/2024 (Estimated)PFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/APRQRProQR Therapeutics-$30.43M-$0.39N/AN/AN/A-431.65%-56.71%-19.15%5/21/2024 (Estimated)PRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/ALatest CYCN, PRVB, EVFM, PFSCF, and PRQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023EVFMEvofem BiosciencesN/A-$0.44-$0.44-$0.44N/A$4.84 million3/13/2024Q4 2023PRQRProQR Therapeutics-$0.08-$0.08N/A-$0.08$27.88 million$3.54 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCNCyclerion TherapeuticsN/A3.853.85EVFMEvofem BiosciencesN/A0.130.10PFSCFProMetic Life SciencesN/A0.950.71PRQRProQR Therapeutics0.103.543.54PRVBProvention Bio0.191.931.92OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCNCyclerion Therapeutics75.62%EVFMEvofem Biosciences0.22%PFSCFProMetic Life Sciences0.10%PRQRProQR Therapeutics32.65%PRVBProvention Bio37.39%Insider OwnershipCompanyInsider OwnershipCYCNCyclerion Therapeutics13.10%EVFMEvofem Biosciences0.21%PFSCFProMetic Life SciencesN/APRQRProQR Therapeutics8.40%PRVBProvention Bio13.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYCNCyclerion Therapeutics12.71 million2.36 millionNo DataEVFMEvofem Biosciences3755.46 million53.85 millionNot OptionablePFSCFProMetic Life Sciences48723.31 millionN/ANot OptionablePRQRProQR Therapeutics15681.36 million74.52 millionOptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableCYCN, PRVB, EVFM, PFSCF, and PRQR HeadlinesSourceHeadlineMacrogenics Inc MGNXmorningstar.com - December 29 at 11:00 PMAnd for Wegovy's Next Trick, Full-Blown Cardiovascular Benefit Outside Diabetesmedpagetoday.com - November 13 at 5:48 PMTeplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetesnejm.org - October 24 at 9:51 AMFDA sets August decision date for Provention's type 1 diabetes drugpharmaphorum.com - July 23 at 5:52 PMLarry Pine Biography & Moviestribute.ca - June 27 at 3:22 PMSanofi/Provention: innovative diabetes drug is a good fitfinance.yahoo.com - May 1 at 10:47 AMThose who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%finance.yahoo.com - April 29 at 9:55 AMSanofi completes Provention Bio acquisitionseekingalpha.com - April 28 at 9:22 AMSanofi concludes acquisition of Provention Biomedicaldialogues.in - April 28 at 4:06 AMSanofi completes acquisition of Provention Bio, Inc.pharmiweb.com - April 28 at 4:06 AMEarnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to Declinefinance.yahoo.com - April 27 at 1:01 PMSanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.finanznachrichten.de - April 27 at 2:00 AMProvention Bio gains after HSR waiting period for Sanofi deal expiredseekingalpha.com - April 26 at 3:59 PMPress Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.benzinga.com - April 26 at 10:51 AMSanofi’s $2.9 Billion Provention Bio Deal Draws Investor Lawsuitnews.bloomberglaw.com - April 25 at 11:24 PMPRVB Apr 2023 23.000 putfinance.yahoo.com - April 22 at 10:13 AMSanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Informationmsn.com - April 11 at 3:59 PMProvention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their Estimatesfinance.yahoo.com - April 2 at 10:41 AMGaithersburg’s Novavax locks in consulting deal with outgoing R&D headbizjournals.com - March 27 at 7:11 PM(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?benzinga.com - March 17 at 7:02 PMQ4 2022 MacroGenics Inc Earnings Callfinance.yahoo.com - March 16 at 9:12 AMProvention Bio's Earnings Outlookbenzinga.com - March 15 at 2:10 PMSMBC Nikko Downgrades Provention Bio (PRVB)msn.com - March 14 at 10:52 PMJefferies Downgrades Provention Bio (PRVB)msn.com - March 14 at 10:52 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCyclerion TherapeuticsNASDAQ:CYCNCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Evofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.ProMetic Life SciencesOTCMKTS:PFSCFPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.ProQR TherapeuticsNASDAQ:PRQRProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.